These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

960 related articles for article (PubMed ID: 12724480)

  • 1. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
    Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
    N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
    Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
    Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
    Johnstone J; Eurich DT; Minhas JK; Marrie TJ; Majumdar SR
    Clin Infect Dis; 2010 Jul; 51(1):15-22. PubMed ID: 20504233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.
    Vila-Córcoles A; Ochoa-Gondar O; Llor C; Hospital I; Rodríguez T; Gómez A
    Eur Respir J; 2005 Dec; 26(6):1086-91. PubMed ID: 16319340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and outcomes of older adults with community-acquired pneumococcal bacteremia.
    Chi RC; Jackson LA; Neuzil KM
    J Am Geriatr Soc; 2006 Jan; 54(1):115-20. PubMed ID: 16420207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.
    Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X
    Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia.
    Fisman DN; Abrutyn E; Spaude KA; Kim A; Kirchner C; Daley J
    Clin Infect Dis; 2006 Apr; 42(8):1093-101. PubMed ID: 16575726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal vaccination in older adults.
    Marras TK
    N Engl J Med; 2003 Aug; 349(7):712-4; author reply 712-4. PubMed ID: 12924340
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults.
    Nelson JC; Jackson M; Yu O; Whitney CG; Bounds L; Bittner R; Zavitkovsky A; Jackson LA
    Vaccine; 2008 Sep; 26(38):4947-54. PubMed ID: 18662735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan.
    Kawakami K; Ohkusa Y; Kuroki R; Tanaka T; Koyama K; Harada Y; Iwanaga K; Yamaryo T; Oishi K
    Vaccine; 2010 Oct; 28(43):7063-9. PubMed ID: 20723631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal vaccine in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness.
    Simberkoff MS
    Semin Respir Infect; 1993 Dec; 8(4):294-9. PubMed ID: 7938926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study.
    Ochoa-Gondar O; Vila-Corcoles A; Ansa X; Rodriguez-Blanco T; Salsench E; de Diego C; Raga X; Gomez F; Valdivieso E; Fuentes C; Palacios L;
    Vaccine; 2008 Apr; 26(16):1955-62. PubMed ID: 18343541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumococcal polysaccharide vaccine may not prevent hospitalization for pneumonia in elderly individuals.
    Skull SA; Andrews RM; Byrnes GB; Kelly HA; Nolan TM; Brown GV; Campbell DA
    Clin Infect Dis; 2007 Feb; 44(4):617; author reply 617-8. PubMed ID: 17260423
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study.
    Hechter RC; Chao C; Jacobsen SJ; Slezak JM; Quinn VP; Van Den Eeden SK; Tseng HF
    Vaccine; 2012 Aug; 30(38):5625-30. PubMed ID: 22789510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents.
    Nuorti JP; Butler JC; Crutcher JM; Guevara R; Welch D; Holder P; Elliott JA
    N Engl J Med; 1998 Jun; 338(26):1861-8. PubMed ID: 9637804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine.
    Li ST; Tancredi DJ
    Pediatrics; 2010 Jan; 125(1):26-33. PubMed ID: 19948570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bacteremic pneumococcal pneumonia].
    Pineda Solas V; Pérez Benito A; Domingo Puiggros M; Larramona Carrera H; Segura Porta F; Fontanals Aymerich D
    An Esp Pediatr; 2002 Nov; 57(5):408-13. PubMed ID: 12467543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
    De Wals P; Black S; Borrow R; Pearce D
    Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness.
    Fedson DS
    Semin Respir Infect; 1993 Dec; 8(4):285-93. PubMed ID: 7938925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
    Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
    Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.